- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02605057
Dermatopharmacokinetic Trial of LEO 80185 Gel
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study consists of two phases:
The pilot: The first part, known as the pilot study, will include 8 subjects and will evaluate pharmacokinetic profile of LEO 80185 gel and Dovobet® Ointment by measuring the amount of each of the active ingredients in the stratum corneum.
Pivotal: The second part, known as the pivotal study, is designed to compare the amount of each of the active ingredients at steady state or close-to-steady state between LEO 80185 gel and Dovobet® Ointment. The number of subjects in the pivotal study and the number of application sites for study medications will be based on the results of the pilot study.
The number of subjects included in the trial and design of trial is in line with previous type of DPK trials in Japan and the Japanese guideline
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Tokyo, Japan, 160-0017
- Shinanokai Shinanozaka Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed and dated informed consent form has been obtained.
- Healthy Japanese male subjects according to medical history, physical examination, ECG, vital signs and laboratory tests.
- Aged 20 to 40 years inclusive.
- Subjects with enough skin area for application of the investigational products.
Exclusion Criteria:
- Body Mass Index outside the range 18-25 kg/m²
- History or presence of alcohol or drug abuse.
- History of allergic reaction to any medications.
- Subjects with, or with a history of, systemic or cutaneous disease that could in any way confound interpretation of the trial results (e.g. atopic dermatitis, eczema, psoriasis)
- Known or suspected hypersensitivity to any component of LEO 80185 gel or Dovobet® ointment.
- Known or suspected hepatic, renal or cardiac disorders.
- Known or suspected disorders of calcium metabolism associated with hypercalcaemia or albumin-corrected serum calcium above the reference range from the sample taken during screening.
Subjects with any of the following skin diseases/skin abnormalities that impede the assessment of the application site (back):
- eczema/dermatitis or abnormal pigmentation
- bruises or scars
- inflammation due to sunburn
- history and/or presence of skin allergy such as atopic dermatitis
- history of drug hypersensitivity
- Signs of skin irritation/disease/disorders/symptoms or blemishes at the planned site of application (e.g. erythema, dryness, roughness, scaling, scars, moles, sunburn)
- Subjects suspected of infection based on the infection testing results from the sample taken during screening (Hepatitis B surface antigen, HCV antibiody, HIV antigen/antibody, serological test for syphilis).
- Use of systemic, locally injected or inhaled corticosteroids within 4 weeks of Day 1.
- Use of vitamin D or calcium supplements, or systemic vitamin D analogues within 4 weeks of Day 1.
- Use of any medication (systemic or topical) within 2 weeks of Day 1.
- Subjects who have received treatment with any non-marketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within 4 months of Day 1.
- Current participation in any other interventional clinical trial.
- Previously randomised in this clinical trial.
- Previous or current photo-induced or photo-aggravated disease (e.g. abnormal response to sunlight).
- Exposure to excessive or chronic ultraviolet radiation (e.g. sunlight, sun lamps, tanning booths or photo-therapy) within 4 weeks of Day 1.
- In the opinion of the (sub)investigator, participation in the trial is inappropriate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LEO 80185 gel
LEO 80185 gel will be allocated to 7 different test sites on each subject
|
|
Experimental: Dovobet Ointment
Dovobet Ointment will be allocated to 7 different test sites on each subject
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The amount of calcipotriol in the stratum corneum
Time Frame: 24 hours
|
Concentrations will be used to determine steady state
|
24 hours
|
The amount of betamethasone dipropionate in the stratum corneum
Time Frame: 24 hours
|
Concentrations will be used to determine steady state
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety (Number and type of adverse events)
Time Frame: 24 hours
|
Number and type of adverse events
|
24 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Masahiko Takeshi, MD, Shinanokai Shinanozaka Clinic
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LP0076-1081
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis Vulgaris
-
LEO PharmaCompletedPlaque Psoriasis | Psoriasis VulgarisGermany
-
SoligenixRecruitingPsoriasis | Plaque Psoriasis | Psoriasis VulgarisUnited States
-
LEO PharmaTerminatedPsoriasis | Plaque Psoriasis | Psoriasis VulgarisBelgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
-
PRCL Research Inc.CompletedPlaque Psoriasis | Psoriasis VulgarisCanada, Slovakia, Ukraine
-
Chinese University of Hong KongNot yet recruitingPsoriasis Vulgaris
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University of California, San FranciscoNovartis Pharmaceuticals; National Psoriasis FoundationRecruitingPsoriasis VulgarisUnited States
-
University of California, San FranciscoSun Pharmaceutical Industries LimitedRecruiting
-
Centre for Human Drug Research, NetherlandsJanssen PharmaceuticalsRecruiting
Clinical Trials on LEO 80185 gel
-
LEO PharmaCompletedScalp PsoriasisUnited States
-
LEO PharmaCMIC Co, Ltd. JapanCompleted
-
LEO PharmaCompletedPsoriasis VulgarisUnited States, Canada, United Kingdom, Germany, Romania, France, Poland
-
LEO PharmaCompletedActinic KeratosisUnited States
-
LEO PharmaCompletedScalp PsoriasisCanada, United Kingdom, France
-
LEO PharmaCompletedSkin and Connective Tissue DiseasesJapan
-
LEO PharmaCompleted
-
LEO PharmaCompletedActinic KeratosisUnited States
-
LEO PharmaCompletedActinic KeratosisUnited States
-
LEO PharmaCompleted